Haleon Pakistan Limited (PSX:HALEON)

Market Cap	94.50B +4.0%
Revenue (ttm)	43.11B +15.9%
Net Income	6.37B +39.2%
EPS	54.45 +39.2%
Shares Out	117.05M
PE Ratio	14.83
Forward PE	12.61
Dividend	30.00 (3.68%)
Ex-Dividend Date	Apr 21, 2026

Volume	50,326
Average Volume	93,845
Open	809.00
Previous Close	799.38
Day's Range	800.00 - 816.20
52-Week Range	653.14 - 1,010.00
Beta	0.50
RSI	64.39
Earnings Date	Apr 28, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of consumer healthcare products in Pakistan, rest of Asia, Africa, Australia, North America, the Middle East, and Europe. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products, as well as over-the-counter pharmaceutical products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company also exports its products to Vietnam, ...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 451
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.